Altamira Therapeutics - CYTO Net Assets per Single Share

Altamira Therapeutics (CYTO) maintains an impeccable image in biotechnology due to high confidence in the quality of its developments. Altamira Therapeutics (CYTO) relies on the OligoPhore system, monetizing royalties and the sale of nasal assets. However, geopolitical risks and logistics disruptions complicate international trials. The book value per ordinary share on the GURU.Markets chart reflects the impact of these factors, with the indicator holding around 0.00.

Auris Medical (CYTO): Share Book Value from 07/04/2022 to 01/04/2025

Altamira Therapeutics Ltd - analytical breakdowns and key metrics (CYTO)

- price and consensus price forecast:

Stock Quotes Auris Medical|CYTO - Analyst Forecast Prices

- market capitalization data:

Market Value Altamira Therapeutics Ltd.|CYTO - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Altamira Therapeutics|CYTO - Net Asset Value|Market Capitalization to Book Value Ratio altamiratherapeutics.com|CYTO - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Altamira Therapeutics|CYTO - Long-Term Debt to Capital|Short-Term Debt to Equity Auris Medical|CYTO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Altamira Therapeutics Ltd.

Fundamental company valuation:altamiratherapeutics.com - CYTO

Altamira Therapeutics' development of innovative RNA drug delivery systems requires significant capital expenditures in intangible assets. This metric reflects the residual value of net assets per common share after deducting all liabilities, allowing for an assessment of the business's intrinsic value via the book value per common share indicator on the GURU.Markets platform to determine the capital's defensive potential.

Competitors of Altamira Therapeutics (CYTO)

Accounting Value per Share Haleon Group HLN|KVUE: Book Price of a Share|Net Assets per Single Share VRNA|MENS (jyongbio.com) - Net Asset Value per Share|Net Assets per Single Share Ligand LGND|Share Book Value Amneal Pharmaceuticals, Inc.|Perrigo Company (PRGO) - Book Value per Share|Accounting Value of a Share Alvotech Biopharmaceuticals (ALVO)|Book Value per Share LQDA (Liquidia Corporation)|glpg.com - Book Value per Share|Net Assets per Single Share ANI Pharmaceuticals, Inc. (ANIP)|MNKD: Accounting Value of a Share|AMPH (Amphastar) - Net Assets per Single Share|Pacira Corp (PCRX) - Accounting Value per Share|SPRY (ARS Pharmaceuticals) - Book Value per Share|Book Value per Share theravance.com (TBPH)|Aquestive Therapeutics, Inc. (AQST) - Accounting Value per Share|Accounting Value of a Share SCPH (scpharmaceuticals.com)|TECX: Net Assets per Single Share|TNXP - Net Asset Value per Share|Accounting Value per Share SXT China SXTC|EPRX - Book Price of a Share|Book Value per Share BioHarvest Sciences Inc. BHST|Invizyne Technologies (EXOZ) - Accounting Value of a Share|Book Value per Share ORMP (Oramed)|Net Asset Value per Share ENTX|MindWalk Holdings (HYFT) - Net Assets per Single Share|Accounting Value of a Share abvcpharma.com (ABVC)|Book Value per Share CPIX (Cumberland Pharmaceuticals Inc.)|Quantum BioPharma Ltd. - Book Value per Share|FGEN - Net Assets per Single Share|Telomir Pharmaceuticals Corp (TELO) - Net Assets per Single Share|RANI - Accounting Value per Share|Synergy CHC (SNYR) - Book Price of a Share|RLYB (Rallybio Corp) - Book Value per Share|Book Value per Share LEXX|Net Assets per Single Share PULM (Pulmatrix Corp)|Accounting Value per Share ftzy.com.cn (PTHL)|Book Value per Share APM|lyratherapeutics.com - Net Assets per Share|Net Assets per Single Share Impact BioMedical Inc (IBO)|TNFA - Accounting Value of a Share|YCBD: Book Value per Share|Book Value per Share PainReform Corp|LIPO - Accounting Value per Share|Accounting Value of a Share optinose.com (OPTN)|Accounting Value per Share Pieris Pharmaceuticals, Inc.|Book Price of a Share Procaps Group (PROC)|Book Value per Share Petros|Accounting Value of a Share Qilian International Corp QLI|SLRN (Acelyrin, Inc.) - Book Value per Share|TFFP: Net Asset Value per Share